Home > Authors and editors

Shashwat Sharad

Uniformed Services University of the Health Sciences

Dr. Sharad works as a Staff Scientist at Center for Prostate Disease Research, Uniformed Services University. He received his Ph.D. in Biochemistry from AAIDU, Allahabad, in collaboration with BITS, Pilani, India. He is an established cancer and translational researcher with a strong academic/administrative track record and leadership qualities. He has inventive research experience in Molecular and Cell Biology, Gene Regulation and Functions, Translational Genomics, Molecular Mechanisms, Bio-specimen Resources and Banking, Molecular Diagnostics and Bioinformatics. His specialized research has focused on diagnosis, early detection, and treatment of human diseases. He was involved in the development of novel point-of-care (POC) device for early detection and testing antibiotic sensitivity of pathogens found in human urine, with commercial value. He is the recipient of several fellowships and grant awards; has published ~20 peer-reviewed articles and 03 book chapters.

1books edited

2chapters authored

Latest work with IntechOpen by Shashwat Sharad

Antisense Therapy offers a comprehensive, state-of-the art perspective on the role of antisense therapy in the treatment of human disease, with a special focus on cancer. Use of antisense oligonucleotides is a growing field of pharmaceutical and biotech companies and research programs for treatment of several diseases. This book summarizes and presents the best updates, therapeutic principles, methods, and applications in the field and offers meaningful information to move treatment discovery forward.

Antisense Therapy

Antisense Therapy

Edited by Shashwat Sharad

Chapters authored

Role of Opioidergic System in Humoral Immune Response

By Suman Kapur, Anuradha Pal and Shashwat Sharad

Part of the book: Immunosuppression

Antisense Therapy: An Overview

By Shashwat Sharad

Nucleic acids are the backbone of antisense therapy. Antisense oligonucleotide-based therapeutics involves downregulation of gene expression. RNA-based drugs that include antisense oligonucleotides bear great therapeutic potential toward treatment of various diseases by altering RNA and/or reducing, restoring, and modifying protein expression through multiple molecular mechanisms. Pharmacology of targeted antisense therapy has provided the platform to translate its utility to the clinic. Over the years, chemical modifications of antisense oligonucleotides have not only enhanced the specificity and efficacy but also reduced the side effects. These have changed the whole clinical trial design and provide newer strategies for therapies. Improvement in antisense oligonucleotide therapy technology has allowed and brought research from bench to clinic. Additionally, the use of small interfering RNAs, micro RNAs, ribozymes, and other antisense compounds toward the treatment of deadly diseases like cancers have demonstrated both preclinical and clinical responses. Furthermore, antisense therapy has great potential to target specific genes of interest in the context of precision medicine. Optimization of enhanced delivery, specificity, affinity, and nuclease resistance with reduced toxicity is underway in different disease context. This chapter gives a complete overview of antisense therapy and highlights its potential. Here, we focused on the advances of the antisense technology, pharmacology, therapeutics, and drug discovery.

Part of the book: Antisense Therapy

Related collaborators

Frederick Tam

Imperial College London , United Kingdom

Stephen McAdoo

Imperial College London , United Kingdom

Suman Kapur

Birla Institute of Technology and Science, Pilani , India

Subhra Biswas

A*STAR-NUS Clinical Imaging Research Centre , Singapore

Hiroko Ishiniwa

Niigata University , Japan

Kazuhiro Sogawa

Tohoku University , Japan

Ken-Ichi Yasumoto

Tohoku University , Japan

Nobuhiko Hoshi

Kobe University , Japan

Anuradha Pal

Birla Institute of Technology and Science, Pilani , India

Irina N. Shalova

Singapore Immunology Network , Singapore